The evidence should suggest that a possible way to enhance the anti-cancer activity of vitamin D3 is to increase 1,25(OH)2D3 effect by reducing the inhibitory action of CYP24A1, with molecules such as KD-35 or 4,5,6,7-tetrabromobenzimidazole (TBBz). This evidence concerns the gene CYP24A1 and cancer.